Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure
The Journal of Infectious Diseases · 2024
DOI: 10.1093/infdis/jiae079 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Yingyan Lu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute of Integrative Medicine, Zhejiang Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine…. Hauptthemen laut MEDLINE: c-Mer Tyrosine Kinase, Acute-On-Chronic Liver Failure, Biomarkers, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic Public Welfare Research Project of Zhejiang Province, Zhejiang Provincial Medical and Health Science and Technolog, Zhejiang Provincial Medical and Health Science and Technology Plan.
Abstract (Originalsprache)
Background
Hepatitis B virus–related acute-on-chronic liver failure (HBV-ACLF) has a high short-term mortality. This study aimed to determine the diagnostic and prognostic role of MER tyrosine kinase (MERTK) in patients with HBV-ACLF.
Methods
Transcriptomics analysis evaluated MERTK expression and function during disease progression. The diagnostic and prognostic significance of MERTK for patients with HBV-ACLF were verified by enzyme-linked immunosorbent assay, area under the receiver operating characteristic curve (AUROC) analysis, and immunohistochemistry (IHC) of liver tissues.
Results
MERTK mRNA was highly expressed in patients with HBV-ACLF compared to those with liver cirrhosis (LC), chronic hepatitis B (CHB), and normal controls (NC). Elevated MERTK mRNA predicted poor prognosis for HBV-ACLF at 28 and 90 days (AUROC = 0.814 and 0.731, respectively). Functional analysis showed MERTK was significantly associated with toll-like receptor and inflammatory signaling and several key biological processes. External validation with 285 plasma subjects confirmed the high diagnostic accuracy of plasma MERTK for HBV-ACLF (AUROC = 0.859) and potential prognostic value for 28- and 90-day mortality rates (AUROC = 0.673 and 0.644, respectively). Risk stratification analysis indicated higher mortality risk for patients with plasma MERTK level above the cutoff value. Moreover, IHC staining showed increasing MERTK expression from NC, CHB, and LC to HBV-ACLF.
Conclusions
MERTK shows promise as a candidate biomarker for early diagnosis and prognosis of HBV-ACLF.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Institute of Integrative Medicine, Zhejiang Key Laboratory of Cancer Prevention and Therapy Combining Traditional Chinese and Western Medicine, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of…
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative National Clinical Research Center for Infectious Diseases, The First Affi…
- Precision Medicine Center, Taizhou Central Hospital, Taizhou University Hospital, Taizhou, China.
Förderung
- Basic Public Welfare Research Project of Zhejiang Province
- Zhejiang Provincial Medical and Health Science and Technolog
- Zhejiang Provincial Medical and Health Science and Technology Plan
Zitieren
APA
Lu, Y., Xin, J., Liang, X., Luo, J., Li, P., Zhou, X., Yang, H., Li, J., & Wang, Y. (2024). Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae079
Vancouver
Lu Y, Xin J, Liang X, Luo J, Li P, Zhou X, et al. Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae079
BibTeX
@article{Lu2024,
author = {Lu, Yingyan and Xin, Jiaojiao and Liang, Xi and Luo, Jinjin and Li, Peng and Zhou, Xingping and Yang, Hui and Li, Jun and Wang, Yifan},
title = {Plasma MERTK Is a Promising Biomarker for the Diagnosis and Prognosis of Hepatitis B Virus–Related Acute-on-Chronic Liver Failure},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae079}
}
EUVIMED